Objectives: To develop evidence-based guideline recommendations through a systematic
review of the literature to establish standard molecular biomarker testing of colorectal cancer …

KRAS is the most frequently mutated oncogene in cancer and KRAS mutation is commonly
associated with poor prognosis and resistance to therapy. Since the KRAS oncoprotein is …

KRAS is one of the most frequently mutated oncogenes in cancer, being a potent initiator of
tumorigenesis, a strong inductor of malignancy, and a predictive biomarker of response to …

Colorectal cancer (CRC) is increasingly appreciated as a heterogeneous disease, with
factors such as microsatellite instability (MSI), cancer subsite within the colon versus rectum …

Abstract NRAS mutation at codons 12, 13, or 61 is associated with transformation; yet, in
melanoma, such alterations are nearly exclusive to codon 61. Here, we compared the …

Colorectal cancer (CRC) is the third most common type of cancer and the second leading
cause of cancer deaths worldwide. Surgery or surgery plus radiotherapy and/or …

Translating preclinical studies to effective treatment protocols and identifying specific
therapeutic responses in individuals with cancer is challenging. This may arise due to the …

Background Colorectal cancer (CRC) is a heterogeneous disease with multiple underlying
causative genetic mutations. The B-type Raf proto-oncogene (BRAF) plays an important role …

Posttranslational modifications to the intracellular domain of the EGFR are known to regulate
EGFR functions; however, modifications to the extracellular domain and their effects remain …

A distinct profile of NRAS mutants is observed in each tumor type. It is unclear whether these
profiles are determined by mutagenic events or functional differences between NRAS …